An Open-Label Phase 1b Multi-Arm Study to Evaluate the Safety Tolerability and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Patients With Advanced Melanoma

Go Back to All Clinical Trials

An Open-Label Phase 1b Multi-Arm Study to Evaluate the Safety Tolerability and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Patients With Advanced Melanoma

Brief description of study

If you have been diagnosed with advanced Melanoma, you may qualify to participate in a study evaluating the side effects and effectiveness of various investigational agents combined with Standard of care treatment has on your disease. The main goal of this phase Ib study is to find out the most effective dose level the various investigational agents in combination with Standard of care treatment can best treat advanced melanoma.

Clinical Study Identifier: s16-00095

ClinicalTrials.gov Identifier: NCTs16-00095

Clinical Research Studies

An Open-Label Phase 1b Multi-Arm Study to Evaluate the Safety Tolerability and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Patients With Advanced Melanoma

Brief description of study

Recruitment Status

212-263-4432

646-754-7432